Member Info for bobsson

Two weeks until end of Q3 2022, still to be ticked off on the Roadmap:
- Rococo Launch (public testnet)
- Uniswap-style AMM (testnet)
Still thinking December 2022 will be good for the share price, but looks as if Q1 2023 will be even better!

Tiziana and its very promising clinical scientific pipeline appears to be gaining a lot of attention from the medical world. We await an update before Christmas on the SPMS trial. Yes this is just a waiting game, but the science must work for us to reap the rewards. We know major pharmas are watching TLSA

Good news. Just a waiting game here. If Foralumab works in any one of the three targets we are in for big gains here. If it work on all three we will hit the jackpot. Should be an update on the MS trial before end of 2022.

Heads up. Pump and Dump? Is it you?

Should be an RNS soon. Has the company got the green light from AQSE to transfer over?

What a shockingly poor company this is.

I would be crazy to sell now. I bought them for 2.5p.

Significantly undervalued. But just because TRX have invested the equivalent of 1.5p (?) per share to get here, does not mean share price must trade there? However, I will set a target share price of 1.5p during 2022, based on the upturn in trading and profits of all three (?) TRX divisions. What is the target price for other posters?

Thank ragnarr, Your closing comment is crucial. If these systems are robust and secure the rewards will be huge. As I have stated previously, I think December 22 will be a very interesting month for BLU.

Any reliable future rumours of Putin`s demise or overthrow would put CASP in the buy quick but speculative category. Just my view, currently not holding.

I wonder who they are and why they want 8.5% of MAST Energy.

W. You are suggesting that TRX might be subject to a buyout by a private company? What sort of price do you think would have to be offered to get the deal done. If Harwood acting on behalf of buyers they already own 20% of TRX.

randaman. I was stupid not to sell these when they went intraday to about £2.60 and I was online watching so could have easily sold. I was stupid. I think I need about $2.25 to break even. I am going to hold and wait and see. If the MS trial continues to go well and the additional 8 patients also show health improvements then the share price could easily go towards $5 if a major pharma teams up for a formal trial of Flab. However if the drug does not show medical benefits then TLSA will just cut the project and probably de-list the shares. So I think its all or nothing for me.

Likely to be a big consolidation upon during move to AQSE. At least 100.1?

They are listed on the US "over the counter" market and not on NASDAQ. When they float on NASDAQ you will be able to trade them.

Apparently you can hold AQSE listed companies in a UK stocks and shares ISA.

NOTE. TOOP are not AIM listed. TOOP are listed on the main market FTSE.

Interim results bullet points.

share price up 10% now at 3pm 20th July. Has the new guy prepared his turnaround plan and now going to execute it?

Tea leaves say 6p after two months.